Merck & Co., Inc.
Merck & Co. is a global biopharmaceutical company developing prescription medicines, vaccines, and animal health products across oncology, infectious disease, and cardiometabolic conditions, anchored by Keytruda (~$31.6B in 2025 revenue) and serving patients and providers in approximately 140 countries.
- Company typePublic
- Founded1891
- HeadquartersTokyo, Japan
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Merck & Co., Inc. does
Merck & Co., Inc. (NYSE: MRK), operating as MSD outside the United States and Canada, is a global biopharmaceutical company founded in 1891 and headquartered in Rahway, New Jersey, with a regional headquarters in Tokyo, Japan. The company develops, manufactures, and commercializes prescription medicines, vaccines, biologic therapies, and animal health products across oncology, infectious diseases, cardiometabolic conditions, immunology, and animal health. Its commercial footprint spans approximately 140 countries, supported by roughly 75,000 employees globally (including about 3,300 in Japan), with major regional commercial and manufacturing hubs in the United States, Europe, and Japan.
The company's core technology stack centers on small-molecule discovery, biologics manufacturing, vaccine platforms, and an emerging pipeline of antibody-drug conjugates and bispecific antibodies, supported by more than 85 active R&D programs. Its flagship asset is Keytruda (pembrolizumab), a PD-1 inhibitor that generated approximately $31.6 billion in 2025 revenue and is approved across 30+ tumor-type indications as both a monotherapy and combination backbone. Other commercial assets include Januvia (sitagliptin), Rybelsus (oral semaglutide, partnered), Gardasil/Gardasil 9 (HPV vaccine), and a broad hospital specialty portfolio. R&D investment was approximately $30.5 billion in 2025, representing roughly 28% of revenue.
Merck's revenue model follows the standard branded-pharma mechanics of direct sales to healthcare providers, hospitals, retail pharmacies, and government immunization programs, supplemented by licensing royalties and collaboration income. Pricing combines list-price publication with confidential rebates to payers, pharmacy benefit managers, and government health systems. Revenue concentration is dominated by the United States, with material exposure to Europe, Japan, and emerging markets, and by therapeutic area, with oncology (anchored by Keytruda) representing the single largest revenue pool. The business model is patent-cliff-sensitive, with Keytruda's composition-of-matter exclusivity expiring around 2028, driving active pipeline replenishment and M&A.
Merck & Co., Inc. firmographics
Firmographics- Name
- Merck & Co., Inc.
- Legal name
- Merck & Co., Inc.
- Website
- https://msd.co.jp
- Company type
- Public
- Founded year
- 1891
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Merck & Co. is a global biopharmaceutical company developing prescription medicines, vaccines, and animal health products across oncology, infectious disease, and cardiometabolic conditions, anchored by Keytruda (~$31.6B in 2025 revenue) and serving patients and providers in approximately 140 countries.
- Ownership category
- akta.pro rank
Merck & Co., Inc. industry classification
Industry- Product category
- Prescription Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
Keywords
Where Merck & Co., Inc. is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices6 records
Markets served
Merck & Co., Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: MSD generates the majority of revenue through global sales of prescription pharmaceutical products including Keytruda (pembrolizumab), vaccines, and other branded drugs across oncology, infectious diseases, diabetes, immunology, and cardiovascular/metabolic conditions. Products are sold through direct sales forces and distribution channels to hospitals, pharmacies, and healthcare providers.
- Vaccine Sales: MSD markets and sells vaccines including HPV vaccines (Gardasil, Silvaguard 9), pneumococcal vaccines (Pneumovax), and pediatric vaccines (Rota Tech) through direct sales and public health procurement channels.
- Licensing and Partnership Revenue: MSD receives licensing fees, option exercise payments, and milestone payments through partnerships. Example: Evaxion paid $7.5 million option exercise fee with potential future payments up to $592 million.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Keytruda (pembrolizumab) treatment pricing varies by market and indication |
| Other | Other | Vaccine products priced under national immunization programs and private markets |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Merck & Co., Inc. product offering
Product offeringCore offering
Merck & Co., Inc. develops, manufactures, and sells prescription pharmaceutical medicines and vaccines for oncology, infectious diseases, diabetes, immunology, and cardiovascular/metabolic conditions. Its flagship product Keytruda (pembrolizumab) is a PD-1 inhibitor used across multiple cancer indications. The company also markets vaccines (Gardasil, Pneumovax, RotaTeq) and operates a global R&D pipeline of 85+ programs.
Product overview
MSD is a global pharmaceutical company offering a broad portfolio of innovative medicines and vaccines across multiple therapeutic areas including oncology (Keytruda, Lenvima, Lynparza), vaccines (Gardasil, Silgard 9, Pneumovax 23, RotaTeq), diabetes (Januvia, Rybelsus), infectious diseases (Lagevrio, Isentress), and pulmonary hypertension (Adempas). The company operates through its Japanese subsidiary MSD K.K. (MSD株式会社) and maintains a robust pipeline including PD-1/PD-L1 bispecific antibodies and other novel therapeutics. The portfolio spans prescription pharmaceuticals, vaccines, and specialty medicines distributed through healthcare providers.
Differentiator
Problem solved
Functional benefit
Brands
- MSD Connect: Medical information site for healthcare professionals
- MSD Manual (プロフェッショナル版/家庭版)
- MSD for Mothers
- Kiran Patient Access Programme
Products and services
- Keytruda (pembrolizumab) / キイトルーダ点滴静注100mg
- Januvia (sitagliptin) / ジャヌビア錠
- Rybelsus (oral semaglutide) / リベルサス錠
- Gardasil / ガーダシル水性懸濁筋注シリンジ
- Silgard 9 / シルガード9水性懸濁筋注シリンジ
- Pneumovax 23 / ニューモバックスNPシリンジ
- RotaTeq / ロタテック内用液
- Adempas / アデムパス錠
- Lagevrio (molnupiravir) / ラゲブリオカプセル
- Isentress / アイセントレス錠
- Bridion / ブリディオン静注
- Lenvima / レンビマカプセル
- Lynparza / リムパーザ錠
Quantifiable outcome
- 450 million people reached annually with medicines and vaccines
- +3 more outcomes
Companies that use Merck & Co., Inc.
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Merck & Co., Inc. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Merck & Co., Inc. partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, major acquisition and social impact.
- Google CloudcoreMerck signed a $1 billion partnership with Google Cloud to deploy agentic AI across its R&D, manufacturing, and commercial operations. This marks a major step in the pharmaceutical AI implementation trend, with MSD showcasing practical AI applications during Q1 2026 earnings calls as part of industry-wide shift from AI hype to measurable implementation.
- Terns Pharmaceuticalsmajor acquisitionMerck acquired Terns Pharmaceuticals for $6.7 billion upfront. This was one of seven transactions exceeding $1 billion each during an 'unusually aggressive' M&A environment in Big Pharma during Q1 2026. The deal was part of a surge in pharma M&A totaling over $64 billion in the first four months of 2026.
- Evaxion A/ScoreMSD partnered with Evaxion A/S through a licensing deal that included a $7.5 million option exercise fee with potential future payments of up to $592 million. Evaxion's personalized cancer vaccine EVX-01 demonstrated a 75% objective response rate in Phase 2 trials. The partnership extended Evaxion's cash runway into H2 2027.
- 公益財団法人ジョイセフ (JOICFP)social impactJapan-based NGO partnership under MSD for Mothers global program. JOICFP implemented a maternal health project in Myanmar from March 2019 to October 2023, training over 3,600 community health volunteers and introducing a voucher system to reduce maternal mortality in the Ayeyarwady region.
Scale indicators9 records
Expansion highlights6 records
Merck & Co., Inc. competitors and assessment
Company assessmentDirect peers
- Bristol Myers Squibb: Direct PD-1 competitor via Opdivo; comparable oncology focus (Yervoy, Opdivo combinations), immunology, and cardiovascular franchises. Co-develops next-gen bispecifics (e.g., pumitamig with BioNTech) that compete with Merck's pipeline.
- Johnson & Johnson: Innovative Medicines segment competes across oncology, immunology, and infectious disease, with similar direct-sales GTM, large R&D budget, and global manufacturing footprint. Comparable in scale and therapeutic breadth.
- Eli Lilly: Competitor in oncology and especially diabetes (Mounjaro/Zepbound displaced Keytruda as the world's top-selling drug in Q1 2026). Comparable in R&D intensity and global commercial scale.
- Pfizer: Global Big Pharma with overlapping oncology, vaccines, and infectious disease portfolios (e.g., Comirnaty, Paxlovid, Ibrance, Padcev). Most directly comparable in scale, R&D intensity, and direct-to-HCP sales model.
- Roche: Oncology leader with Tecentriq (PD-L1) competing against Keytruda, plus a biosimilar exposure (loss of MabThera/Herceptin exclusivity mirrors Merck's pending Keytruda cliff). Strong diagnostics integration is a differentiator.
- GSK: Major vaccines peer (Shingrix, Cervarix HPV competitor), plus oncology and HIV/infectious disease franchises. Highly comparable in vaccine scale and specialty pharma model.
- Novartis: Big Pharma peer with overlapping oncology (Pluvicto, Kisqali), cardiovascular, and immunology focus. Similar post-patent-cliff transformation strategy (Sandoz spin-off) and direct-to-HCP sales motion.
- AstraZeneca: Oncology (Imfinzi, Enhertu, Tagrisso) and vaccines/biologics competitor with comparable pipeline depth and accelerated post-COVID growth trajectory. Directly competes in PD-L1 and ADC space.
- Sanofi: Global pharma with strong vaccines (Fluzone, Beyfortus), Dupixent in immunology, and oncology. Comparable in therapeutic diversification and direct-to-HCP sales model.
Regional players
- Takeda Pharmaceutical: Japan-headquartered global pharma peer with overlapping oncology, GI, and rare disease portfolios, and direct domestic competition for MSD K.K. in the Japanese market. Useful Japan-specific comparable.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Merck & Co., Inc. social profiles
Digital presenceMerck & Co., Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Merck & Co., Inc. leadership team
Management profileNumber of profiles
Profiles9 records
Merck & Co., Inc. subsidiaries and ownership
Company hierarchySubsidiaries1 record
Merck & Co., Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Merck & Co., Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Merck & Co., Inc.
What does Merck & Co., Inc. do?
Merck & Co., Inc. develops, manufactures, and sells prescription pharmaceutical medicines and vaccines for oncology, infectious diseases, diabetes, immunology, and cardiovascular/metabolic conditions. Its flagship product Keytruda (pembrolizumab) is a PD-1 inhibitor used across multiple cancer indications. The company also markets vaccines (Gardasil, Pneumovax, RotaTeq) and operates a global R&D pipeline of 85+ programs.
Is Merck & Co., Inc. a public or private company?
Merck & Co., Inc. is a public company. It is classified as public and is currently operating.
When was Merck & Co., Inc. founded?
Merck & Co., Inc. was founded in 1891. It employs 1,001 to 5,000 people.
Where is Merck & Co., Inc. based?
Merck & Co., Inc. is headquartered in Tokyo, Japan, in the Asia region.
How does Merck & Co., Inc. make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are vaccine Sales and licensing and Partnership Revenue.
Who are Merck & Co., Inc.'s main competitors?
Direct peers on record are Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, Pfizer, Roche, GSK, Novartis, AstraZeneca and Sanofi. Takeda Pharmaceutical is listed as a regional player.
Does Merck & Co., Inc. have an API?
No public API is recorded for Merck & Co., Inc..
What industry is Merck & Co., Inc. in?
Merck & Co., Inc.'s product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 325412 and its SIC code is 2834.